NASDAQ NMS - GLOBAL MARKET · AVIR
+1.33% · +$0.0700 · Vol 600.4K
Market closed · last close 4:00 PM ET · price as of 16:16:40 ET
Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc

Pharmaceuticals
$5.33
Card
Relationship Map

Follow $AVIR

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $AVIR by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
AVIR
Atea Pharmaceuticals Inc
Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

73/ 100
Veridion Score
Upper range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is AVIR moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading AVIR catalysts
About Atea Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
55
Country
US

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$5.21
Day high
$5.37
Day low
$5.17
Previous close
$5.26
52W high
$6.15
-13.33% from high
52W low
$2.82
75% of range
Market cap
$427.5M
EPS
$-1.9500
Beta
0.42
Shares out
80.2M
Volume
600.4K
2.29× rel vol
Avg volume
261.8K
VWAP
$5.31
Price history computed in-house
1W
+0.38%
1M
-1.84%
3M
+21.41%
1Y
+85.07%
YTD
+49.30%
SMA 50 $5.12 · above
SMA 200 $4.71 · above
52W position 75%

AVIR overview

Veridion Score
73
Registered · 2026-09-18
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around AVIR.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading AVIR Form 4 filings
Public disclosures

Congress activity in AVIR

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for AVIR in the cached public ledger.

Federal contracts

AVIR contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AVIR in this window.
Lobbying spend

AVIR lobbying filings, year to date.

Registered lobbying filings matched to Atea Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AVIR in this window.
Loading news for AVIR
Analyst ratings
Sovereign unlock shows live analyst consensus for AVIR.
Options
Sovereign unlock shows live options positioning for AVIR.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.